News | July 08, 2009

Tissue Regeneration Used to Rebuild Patients’ Heart Structures

July 8, 2009 - Marc Gerdisch, M.D., director of cardiothoracic surgery at the St. Francis Heart Center and a partner at Cardiac Surgery Associates, is using the CorMatrix Extracellular Matrix (ECM) to modify and repair cardiac structures, allowing heart tissue to regrow inside the beating hearts of heart surgery patients. The CorMatrix ECM is a unique biomaterial that harnesses the body’s innate ability to repair damaged heart tissue. Over time, it is replaced by the patient’s own tissue.

“The use of this biomaterial is a major advancement in cardiac surgery and allows us to provide our patients with restoration of normal anatomic structures. It opens the door to a new level of cardiac tissue reconstruction,” said Dr. Gerdisch.

In August 2007, Dr. Gerdisch, who specializes in complex heart valve surgery, became the first in the world to apply this technology inside the heart, repairing a congenital defect.

“Similar uses of the ECM followed at our and other institutions,” reported Dr. Gerdisch, who is codirector of the St. Francis Midwest Heart Valve Center. “Then, in March 2008, we performed the first enlargement of the path blood follows as it exits in the heart using the CorMatrix ECM, in lieu of a prosthetic device, for a patient undergoing valve surgery.”

The first mitral valve reconstruction using CorMatrix occurred at St. Francis Heart Center in October of 2008. A patient’s valve had developed large defects because of infection. CorMatrix patches restored the valve to normal function and helped avoid a replacement.

“We have been able to make similar repairs for other patients since,” added Gerdisch.

The CorMatrix ECM is derived from porcine small intestines and is processed in a way that removes all cells, leaving the complex structural matrix intact. Once surgically implanted, it serves as a scaffold, allowing the patient’s cells to infiltrate and ultimately replace the ECM scaffold.

While the patient continues to heal, the matrix is gradually replaced as the body reinforces and remodels the tissue. In the past, tissue replacement has been limited by options for implantation.

Animal tissue implants are subject to calcium deposition and hardening because the body recognizes them as foreign. Synthetic material lacks the performance characteristics of tissue and causes an inflammatory response. ECM, however, leads to growth of functional tissue where scarring would normally be expected.

For more information: www.cardiactissuerepair.net

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.
Overlay Init